* Anergen Inc., of Redwood City, Calif., presentedanimal studies demonstrating its drug, IDDM-AnergiX,had positive results against Type I diabetes.
* Aronex Pharmaceuticals Inc., of The Woodlands,Texas, and researchers reported laboratory resultsshowing the anti-HIV oligonucleotide, AR-177, inhibitedviral production by inhibiting the enzyme, HIV integrase.
* Biomira Inc., of Edmonton, Alberta, finalized itsacquisition of privately held OncoTherapeutics Inc., ofCranbury, N.J. (See BioWorld Today, Aug. 30, 1995, p.1.)
* Biomune Systems Inc., of Salt Lake City, formed awholly owned subsidiary, Optim Nutrition Inc., todevelop and commercialize neutraceutical products, suchas its Immuno-C for wasting.
* Cangene Corp., of Toronto, completed its "reverseacquisition" of Rh Pharmaceuticals Inc., of Winnipeg,Manitoba. Rh's parent company, the ApotexPharmaceutical Group, of Toronto, owns 85 percent ofthe new company. (See BioWorld Today, Aug. 1, 1995,p. 1.)
* IBEX Technologies Inc., of Montreal, said a secondPhase I study of Neutralase confirmed its ability toneutralize heparin in humans.
* Parexel International Corp., a Boston-based contractresearch organization, said the Inter-Company Collabo-ration for AIDS Drug Development began its secondresearch study _ one-year trials of 225 HIV patients intwo three-drug regimens: London-based Glaxo Wellcomeplc's AZT and 3TC with New York-based Bristol-MyersSquibb Co.'s ddI; and AZT, ddI and Germany-basedBoehringer Ingelheim GmbH's nevirapine. Thoseregimens will be compared to the combination of AZTand ddI.
* Pharmacia AB, of Stockholm, Sweden, said thoseholding 96 percent of its shares agreed to the merger withThe Upjohn Co., of Kalamazoo, Mich.
(c) 1997 American Health Consultants. All rights reserved.